Cargando…

Management of Recurrent Retroperitoneal Sarcoma

Recurrence after resection of retroperitoneal sarcoma is common and varies by histological subtype. Pattern of recurrence is similarly affected by histology (e.g., well-differentiated liposarcoma is more likely to recur locoregionally, whereas leiomyosarcoma is more likely to develop distant metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Jolissaint, Joshua S., Raut, Chandrajit P., Fairweather, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047230/
https://www.ncbi.nlm.nih.gov/pubmed/36975422
http://dx.doi.org/10.3390/curroncol30030209
_version_ 1785013868713476096
author Jolissaint, Joshua S.
Raut, Chandrajit P.
Fairweather, Mark
author_facet Jolissaint, Joshua S.
Raut, Chandrajit P.
Fairweather, Mark
author_sort Jolissaint, Joshua S.
collection PubMed
description Recurrence after resection of retroperitoneal sarcoma is common and varies by histological subtype. Pattern of recurrence is similarly affected by histology (e.g., well-differentiated liposarcoma is more likely to recur locoregionally, whereas leiomyosarcoma is more likely to develop distant metastases). Radiotherapy may provide effective locoregional control in limited circumstances and the data on the impact of chemotherapy are scant. Surgery for locally recurrent disease is associated with the greatest survival benefit; however, data are retrospective and from a highly selected subgroup of patients. Limited retrospective data have also suggested a survival association with the resection of limited distant metastases. Given the complexity of these patients, multidisciplinary evaluation at a high-volume sarcoma center is critical.
format Online
Article
Text
id pubmed-10047230
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100472302023-03-29 Management of Recurrent Retroperitoneal Sarcoma Jolissaint, Joshua S. Raut, Chandrajit P. Fairweather, Mark Curr Oncol Review Recurrence after resection of retroperitoneal sarcoma is common and varies by histological subtype. Pattern of recurrence is similarly affected by histology (e.g., well-differentiated liposarcoma is more likely to recur locoregionally, whereas leiomyosarcoma is more likely to develop distant metastases). Radiotherapy may provide effective locoregional control in limited circumstances and the data on the impact of chemotherapy are scant. Surgery for locally recurrent disease is associated with the greatest survival benefit; however, data are retrospective and from a highly selected subgroup of patients. Limited retrospective data have also suggested a survival association with the resection of limited distant metastases. Given the complexity of these patients, multidisciplinary evaluation at a high-volume sarcoma center is critical. MDPI 2023-02-25 /pmc/articles/PMC10047230/ /pubmed/36975422 http://dx.doi.org/10.3390/curroncol30030209 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jolissaint, Joshua S.
Raut, Chandrajit P.
Fairweather, Mark
Management of Recurrent Retroperitoneal Sarcoma
title Management of Recurrent Retroperitoneal Sarcoma
title_full Management of Recurrent Retroperitoneal Sarcoma
title_fullStr Management of Recurrent Retroperitoneal Sarcoma
title_full_unstemmed Management of Recurrent Retroperitoneal Sarcoma
title_short Management of Recurrent Retroperitoneal Sarcoma
title_sort management of recurrent retroperitoneal sarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047230/
https://www.ncbi.nlm.nih.gov/pubmed/36975422
http://dx.doi.org/10.3390/curroncol30030209
work_keys_str_mv AT jolissaintjoshuas managementofrecurrentretroperitonealsarcoma
AT rautchandrajitp managementofrecurrentretroperitonealsarcoma
AT fairweathermark managementofrecurrentretroperitonealsarcoma